Department of Genetics and Cell Biology, Clinical Genomics Unit, Maastricht University, Maastricht, The Netherlands.
MHeNs School of Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):342-352. doi: 10.1136/jnnp-2018-319042. Epub 2018 Dec 15.
Neuropathic pain is common in peripheral neuropathy. Recent genetic studies have linked pathogenic voltage-gated sodium channel (VGSC) variants to human pain disorders. Our aims are to determine the frequency of , and variants in patients with pure small fibre neuropathy (SFN), analyse their clinical features and provide a rationale for genetic screening.
Between September 2009 and January 2017, 1139 patients diagnosed with pure SFN at our reference centre were screened for , and variants. Pathogenicity of variants was classified according to established guidelines of the Association for Clinical Genetic Science and frequencies were determined. Patients with SFN were grouped according to the VGSC variants detected, and clinical features were compared.
Among 1139 patients with SFN, 132 (11.6%) patients harboured 73 different (potentially) pathogenic VGSC variants, of which 50 were novel and 22 were found in ≥ 1 patient. The frequency of (potentially) pathogenic variants was 5.1% (n=58/1139) for 3.7% (n=42/1139) for and 2.9% (n=33/1139) for . Only erythromelalgia-like symptoms and warmth-induced pain were significantly more common in patients harbouring VGSC variants.
(Potentially) pathogenic VGSC variants are present in 11.6% of patients with pure SFN. Therefore, genetic screening of and should be considered in patients with pure SFN, independently of clinical features or underlying conditions.
周围神经病变中常见神经病理性疼痛。最近的遗传研究将致病变异体电压门控钠离子通道(VGSC)变异与人类疼痛障碍联系起来。我们的目的是确定纯小纤维神经病(SFN)患者中 、 和 变异的频率,分析其临床特征,并为遗传筛查提供依据。
2009 年 9 月至 2017 年 1 月,我们的参考中心对 1139 例被诊断为纯 SFN 的患者进行了 、 和 变异筛查。根据临床遗传科学协会的既定指南对变异的致病性进行分类,并确定其频率。根据检测到的 VGSC 变异,将 SFN 患者分为不同组,比较其临床特征。
在 1139 例 SFN 患者中,有 132 例(11.6%)患者携带 73 种不同(潜在)致病性 VGSC 变异,其中 50 种为新变异,22 种在≥1 例患者中发现。(潜在)致病性变异的频率为 5.1%(58/1139), 为 3.7%(42/1139), 为 2.9%(33/1139)。只有红斑性肢痛样症状和温热诱导性疼痛在携带 VGSC 变异的患者中更常见。
纯 SFN 患者中有 11.6%携带(潜在)致病性 VGSC 变异。因此,无论临床特征或潜在疾病如何,均应考虑对纯 SFN 患者进行 和 的基因筛查。